Today, 6 March 2026, the Council of the European Union (“Council”) published the provisional agreement on the reform of the EU pharmaceutical legislation and the new Directive [link] and Regulation [link]. Formal adoption by the European Parliament and the Council is expected in the coming months.
Latest Post
More Posts
MHRA Launches Targeted Consultation on Indefinite Recognition of CE‑Marked Medical Devices
UK government sets out 2026 branded medicines Statutory Scheme repayment rate
US-UK Pharmaceutical Pricing Deal: UK agrees increase in amounts it can pay for innovative medicines and reduction of rebate rates
Rewriting the Rulebook: MHRA’s Vision for Rare Disease Therapies
MHRA and NICE launch aligned approvals pathway
UK government and pharmaceutical industry fail to reach agreement on amendments to medicines pricing scheme
ABPI calls for changes to “unsustainable” medicines pricing scheme
The UK’s MHRA launches consultation on draft guideline on individualised mRNA cancer immunotherapies
A New 2024 Code for the British Pharmaceutical Industry – “The Future is Orange”
Subscribe: Subscribe via RSS
Blogs
Firm/Org